Stoma/Ostomy Care Global Market 2022: Sector to Reach $4.1 Billion by 2027 at a CAGR of 4.22%
February 16, 2023 04:23 ET
|
Research and Markets
Dublin, Feb. 16, 2023 (GLOBE NEWSWIRE) -- The "Stoma/Ostomy Care Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ...
Global Gastrointestinal Partnering Report and Directory 2022: Trends by Year, Deal Type, Stage of Development, Technology Type and Therapeutic Indication
December 02, 2022 08:09 ET
|
Research and Markets
Dublin, Dec. 02, 2022 (GLOBE NEWSWIRE) -- The "Global Gastrointestinal Partnering 2015-2022: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering. The...
Global Inflammatory Bowel Disease Treatment Market Research Report 2022 Featuring AbbVie, Biogen, Johnson & Johnson, Amgen, & UCB SA
November 08, 2022 06:13 ET
|
Research and Markets
Dublin, Nov. 08, 2022 (GLOBE NEWSWIRE) -- The "Inflammatory Bowel Disease Treatment Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.The global inflammatory...
Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2022
November 02, 2022 08:00 ET
|
Morphic Therapeutic
Completed enrollment of EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis ahead of schedule EMERALD-2 phase 2b global randomized study of MORF-057 to begin fourth quarter ...
Morphic Presents New Positive MORF-057 Phase 1 Data at American College of Gastroenterology Annual Meeting 2022
October 25, 2022 16:05 ET
|
Morphic Therapeutic
Saturating receptor occupancy at 100 and 200 mg BID doses Statistically significant effects on key lymphocyte subsets WALTHAM, Mass., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq:...
Morphic Announces Complete Enrollment of EMERALD-1 Main Cohort Ahead of Projections
October 24, 2022 08:00 ET
|
Morphic Therapeutic
WALTHAM, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022
October 10, 2022 08:00 ET
|
Morphic Therapeutic
200 mg BID dose demonstrates receptor saturation and statistically significant increases in key circulating T lymphocyte populations Lymphocyte changes consistent with approved α4β7 inhibitor ...
Global Inflammatory Bowel Disease Treatment Market Is Expected to Reach $34.5 Billion by 2031: Allied Market Research
September 08, 2022 08:59 ET
|
Allied Market Research
Portland, OR, Sept. 08, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Inflammatory Bowel Disease Treatment Market generated $21.0 billion in 2021,...
First Wave BioPharma to Present at H.C. Wainwright 24th Annual Global Investment Conference 2022
August 29, 2022 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Aug. 29, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma, Inc. Announces Reverse Stock Split
August 25, 2022 12:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Aug. 25, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...